- Maine AG Aaron Frey announced a settlement with Sanofi-Aventis U.S. LLC to resolve allegations that the pharmaceutical company’s deceptive pricing policies resulted in underinsured and uninsured patients having to pay higher list prices for insulin.
- According to the AG’s office, Sanofi will cap out-of-pocket insulin costs at $35 per month for Maine consumers through 2029. The company also agreed to launch an enrollment message program to notify pharmacists when patients qualify for lower-cost alternatives.
- The AG’s office urges consumers to ask their pharmacists about their eligibility for low-cost insulin when filling prescriptions.
- Other AGs have negotiated similar insulin price caps with pharmaceutical companies, including Minnesota AG Keith Ellison and New York AG Letitia James.